A Careful, Honest Comparison
ChondroFiller® vs
MACI
MACI is the cell-based gold standard for medium-to-large knee cartilage defects — a two-stage surgical procedure backed by NICE-approved NHS use. ChondroFiller® is a single-stage scaffold injection without the cell-harvest step. Here is the honest comparison.
Reviewed byProf Paul Lee MBBch, FRCS (Tr & Orth), PhDLast reviewed 1 May 2026Quick Answer
ChondroFiller® is a single-stage scaffold injection; MACI is a two-stage cell-based surgical implant. MACI is recommended by NICE for selected knee cartilage defects (typically 2–10 cm²) and is delivered on the NHS for eligible patients. It involves a cartilage biopsy, four to six weeks of laboratory cell culture and a second surgery to implant the cell-loaded membrane. ChondroFiller® avoids the cell-harvest and culture step: the scaffold is placed in a single ultrasound-guided injection, and the body’s own cells migrate in to form new tissue. The right choice depends on defect size, location, age and what the imaging shows.
The Headline Difference
ChondroFiller® vs MACI — the key difference
MACI is a cell-based therapy: a small piece of the patient’s own cartilage is harvested at an arthroscopy, chondrocytes are cultured in a specialist lab for four to six weeks, and the cell-loaded collagen membrane is then implanted at a second surgery. ChondroFiller® instead delivers a sterile collagen scaffold in a single injection — there is no cell harvest, no lab culture and no second procedure. Both aim for more hyaline-like repair tissue rather than fibrocartilage, but the route to get there is very different.
Mechanism of Action
How each treatment works
ChondroFiller® is a sterile type I/III collagen scaffold injected as a liquid directly into a mapped cartilage defect under ultrasound guidance. It sets into a gel that occupies the defect within minutes.
The patient’s own cells then migrate into the scaffold and lay down new cartilage matrix over six to twelve months. Single-stage. No cell harvest. No lab phase.
MACI involves two surgical procedures. First, an arthroscopy harvests a small piece of cartilage from a non-weight-bearing area. The chondrocytes are then sent to a specialist laboratory where they are expanded onto a porcine type I/III collagen membrane over four to six weeks.
The cell-loaded membrane is then implanted into the prepared defect at a second open or mini-open surgery, secured with fibrin glue. The patient is left to mature the implant through a prescriptive rehabilitation protocol.
How Long Results May Last
Duration and number of injections
Tissue formation over 6–12 months
Durable in published series at 10+ years
MACI has the longer follow-up record because it has been on the market longer. The clinical question is not which technique has been studied for longer but which one fits the defect on imaging.
Treatment Course
Number of injections
Typically one injection course, with the box quantity (one, two or three) decided from MRI. ChondroFiller® can be repeated for a separate new defect if needed; the originally implanted tissue is intended to be durable.
MACI is a one-off two-stage course: arthroscopic biopsy, laboratory expansion, then a second implantation surgery. A repeat MACI would require a fresh biopsy and full cell expansion again.
Safety and Infection
Safety considerations
These procedures sit at very different points on the invasiveness scale. ChondroFiller® at London Cartilage Clinic is an ultrasound-guided outpatient injection with routine IV antibiotic cover; the most serious risk is joint infection, which is rare.
MACI involves two surgeries, with the standard surgical risk profile — infection, deep-vein thrombosis, anaesthetic risks at each operation — plus implantation-specific concerns including graft delamination, hypertrophy and the need for a prescriptive rehabilitation programme. The cell handling and traceability is tightly regulated under UK ATMP rules.
Patient Selection
Who each treatment may suit
MACI is recommended for medium-to-large symptomatic knee cartilage defects in adults (typically 2–10 cm²) with otherwise reasonably preserved joints and motivated patients who can complete the rehabilitation. It is delivered through specific NHS centres for selected NICE-eligible patients, and privately at a few UK centres.
ChondroFiller® is appropriate for focal cartilage defects up to roughly 6 cm² with reasonably preserved surrounding cartilage. It is delivered as an injection, which suits patients who want to avoid open surgery or who are not eligible for or willing to wait for MACI. See who is suitable for ChondroFiller?
Cost and Value
What each treatment costs
At London Cartilage Clinic, ChondroFiller® costs from £3,000 for one box, £5,500 for two and £8,000 for three, all-in. See the ChondroFiller® cost guide.
Private MACI typically costs £30,000 to £40,000 or more in the UK because the cell processing, laboratory expansion and two surgeries are all expensive. On the NHS, MACI is provided free for clinically eligible patients via specific commissioned centres, though access can vary by region and pathway.
For NICE-eligible patients with an NHS-available pathway, MACI is often the more efficient choice. Privately, the price gap and the single-stage nature of ChondroFiller® can make it the more accessible regenerative option for the right defect.
Our Honest Take
When we may recommend each
A focal cartilage defect on MRI where a single-stage scaffold injection is reasonable.
You want to avoid open surgery and the two-stage MACI pathway, where the defect size and location support a non-surgical option.
You are private-pay and the £30k+ MACI cost is not a route you want to take when a scaffold injection is a clinically reasonable alternative.
Medium-to-large symptomatic knee cartilage defects (typically 2–10 cm²) in a motivated patient who can complete the rehabilitation.
NICE-eligible patients with access to an NHS MACI pathway, where the procedure is funded and the surgical team has the volume.
Cases where the surgeon judges that a cell-based, surgically implanted, scaffold is the right answer for the size and location of the defect.
When Each Is The Wrong Answer
When we would not recommend each
Very large or multi-zone defects where a surgical cell-based or co-delivery procedure (MACI or Liquid Cartilage™ keyhole surgery) is more appropriate.
Unstable subchondral bone or significant bone marrow oedema requiring a bony component to the procedure.
Diffuse bone-on-bone arthritis where no focal-defect technique will help.
Very small focal defects where the two-stage cell-based pathway is over-treatment.
Patients unable to commit to the prescriptive rehabilitation programme MACI requires.
Patients with general contraindications to open knee surgery, where a scaffold injection may be a reasonable alternative.
The Bottom Line
In summary
MACI is the long-established, cell-based standard for medium-to-large knee cartilage defects, and it should remain the first thought for NICE-eligible NHS patients. ChondroFiller® is a different proposition: a single-stage scaffold injection, no cell harvest, no laboratory phase, no second surgery. The right answer depends on defect size, location and what is available to you. We will tell you honestly when MACI is the better path.
ChondroFiller® vs MACI
Frequently asked questions
Is ChondroFiller® a cheaper version of MACI?
They are not the same procedure. MACI is a cell-based two-stage surgical implant using the patient’s own chondrocytes cultured in a lab. ChondroFiller® is a single-stage scaffold injection that recruits the body’s own cells in situ. The price gap reflects the underlying procedure complexity, not a discounted version of the same thing.
If MACI is available on the NHS, why would I have ChondroFiller® privately?
If you are NICE-eligible and an NHS MACI pathway is accessible, MACI is often the right first thought. People choose ChondroFiller® when MACI is not appropriate for the defect, when they cannot wait, when they want a single-stage injection over a two-stage surgery, or when their defect sits outside the MACI eligibility window.
Can ChondroFiller® be used after MACI has failed?
Sometimes yes — where the failed MACI has left a contained defect with reasonably stable surrounding tissue, ChondroFiller® can occasionally be considered. Where the bone is irregular or the joint has progressed to broader arthritis, a different procedure may be needed. We review the post-MACI imaging before deciding.
Does ChondroFiller® avoid the rehabilitation MACI requires?
Not entirely. New tissue forms over six to twelve months and benefits from graded loading, but the rehabilitation programme is generally less prescriptive than after MACI because the subchondral bone has not been operated on and there is no implanted membrane to protect.
Is the repair tissue the same?
Both procedures aim for more hyaline-like repair tissue rather than the fibrocartilage produced by marrow-stimulation techniques such as microfracture. The cellular source is different — MACI uses the patient’s own expanded chondrocytes, ChondroFiller® uses the cells that migrate into the scaffold in situ — but the goal is the same hyaline-like biology.
How does the evidence base compare?
MACI has been on the market longer and has the longer follow-up record, including ten-year cohorts. ChondroFiller® has a younger but still substantial publication record (IKDC, Harris Hip Score, MOCART MRI), with over 19,000 cases of clinical use across joints. See the ChondroFiller® clinical evidence page.
Book a ChondroFiller® Assessment – London
Natural cartilage regeneration starts with the right defect, the right operator, and the right plan.
Learn More about ChondroFiller
Deep dive into our clinical resources and patient guides.
Cost in the UK
ChondroFiller® cost in the UK from £3,000, what is included and why prices vary.
Suitability
Who is suitable for ChondroFiller® as an injection, and who may need caution.
Clinical Evidence
IKDC, Harris Hip Score and MOCART MRI outcomes for ChondroFiller® cartilage regeneration.
Self-Assessment
Five-question ChondroFiller® pathway self-assessment for Prevention, Regeneration, Combination, or Support.
In London
Private ChondroFiller® cartilage repair at our Harley Street clinic.
Liquid Cartilage™ Surgery
Our proprietary keyhole-surgery technique combining ChondroFiller® with MSC co-delivery in a single procedure, for larger or more complex cartilage defects. £9,800.
ChondroFiller vs Arthrosamid
Cartilage regeneration vs joint cushioning, two very different injections.
ChondroFiller vs Hyaluronic Acid
Structural scaffold for cartilage regeneration vs joint-lubricant viscosupplement.
ChondroFiller vs Microfracture
ChondroFiller® regeneration compared to microfracture surgery for cartilage defects.
ChondroFiller vs MACI
ChondroFiller® scaffold compared to matrix-induced autologous chondrocyte implantation.
ChondroFiller vs ACI
ChondroFiller® scaffold compared to the original autologous chondrocyte implantation technique.
ChondroFiller vs PRP
ChondroFiller® cartilage regeneration compared to platelet-rich plasma injection.
ChondroFiller vs Stem Cells
ChondroFiller® compared to stem cell and biologic regenerative treatments.
ChondroFiller vs Knee Replacement
Where ChondroFiller® may help preserve the joint and where replacement is the right answer.
ChondroFiller® Injection
Cartilage Regeneration Overview
ChondroFiller® is a registered trademark of Meidrix Biomedicals GmbH. London Cartilage Clinic is not affiliated with or endorsed by Meidrix Biomedicals.